Takeda Supports Crohn’s and Colitis Canada PACE Network with $500,000 contribution

Takeda Canada Inc. announced its support for the Promoting Access and Care through Centres of Excellence (PACE) network and will be contributing $125,000 per year over four years, for a total of $500,000.

The Crohn’s and Colitis Canada PACE network is a unique charity-pharmaceutical industry collaboration that aims to improve quality of life for patients living with Crohn’s disease and ulcerative colitis – the two main forms of inflammatory bowel disease (IBD) – through the establishment of a national network of IBD Centres of Excellence.

“PACE brings together world-class patient care and research centres to advance the standard of care for Canadians living with Crohn’s disease and ulcerative colitis,” said Mina Mawani, President and CEO of Crohn’s and Colitis Canada. “Support from Takeda Canada and other industry partners is essential to the success of initiatives like PACE for the benefit of patients living with chronic diseases.”

Today’s announcement coincides with launch events at several of the IBD centres of excellence participating in the PACE network: Mount Sinai Hospital, McMaster University, and McGill University including research leads in each centre, pharmaceutical industry representatives, patients, and government dignitaries.

“Takeda Canada places great importance on its work in gastroenterology and IBD in particular. We recognize the challenges that people living with IBD face on a daily basis which is why we strive to help meet the needs of Canadian patients in as many ways as we can,” said Chatrick Paul, General Manager, Takeda Canada Inc. “It was clear to us that we needed to be involved in PACE because it identified crucial gaps in patient care and proposed very concrete plans to fill them. We are very pleased to support this network and look forward to seeing the results.”
Takeda Canada is a strong supporter of Crohn’s disease and ulcerative colitis research in Canada. The company’s support of the PACE network is the second major investment this year. Takeda recently invested $2.1 million in the Strategy for Patient-Oriented Research (SPOR) patient-centred gastrointestinal research initiative, IMAGINE, led by McMaster University.


The Canadian Business Quarterly (The CBQ) provides an in-depth view of business and economic development issues taking place across the country. Featuring interviews with top executives, government policy makers and prominent industry bodies The CBQ examines the news beyond the headlines to uncover the drivers of local, provincial, and national affairs.

All copy appearing in The Canadian Business Quarterly is copyrighted. Reproduction in whole or part is not permitted without written permission. Any financial advice published in The Canadian Business Quarterly or on www.thecbq.ca has been prepared without taking in to account the objectives, financial situation or needs of any reader. Neither The Canadian Business Quarterly nor the publisher nor any of its employees hold any responsibility for any losses and or injury incurred (if any) by acting on information provided in this magazine or website. All opinions expressed are held solely by the contributors and are not endorsed by The Canadian Business Quarterly or www.thecbq.ca.

All reasonable care is taken to ensure truth and accuracy, but neither the editor nor the publisher can be held responsible for errors or omissions in articles, advertising, photographs or illustrations. Unsolicited manuscripts are welcome but cannot be returned without a stamped, self-addressed envelope. The publisher is not responsible for material submitted for consideration. The CBQ is published by Romulus Rising Pty Ltd, ABN: 77 601 723 111.


© 2023 The Canadian Business Quarterly. All rights reserved. A division of Romulus Rising Pty Ltd, an Australian media company (www.RomulusRising.com).